Download
December 14, 2021 09:15 AM Eastern Standard Time
BOSTON--( BUSINESS WIRE )-- binx health , a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today that CB Insights ranked binx health among the most promising digital health startups in the world. The Digital Health 150 is a list of 150 of the top private companies using digital technology to transform healthcare. binx health is included in the Screening, Monitoring, and Diagnostics category. Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. This year's Digital Health 150 was unveiled live during CB Insights' annual Future of Health event. The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns . Companies this year include startups working on data integration and analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more. "This year's Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging," said Brian Lee, SVP of CB Insights' Intelligence Unit. "We are honored to be included in this impressive list of companies that are all helping to reimagine healthcare for coming generations,” said Jeff Luber , binx health chief executive officer. “This recognition is a testament to the innovative spirit, hard work, and sacrifices of our people. It is also further validation that our platform and vision are aligned with the future." About binx health
binx health is a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop. The Company works with large corporate partners and institutions who have access to large patient populations and have a significant interest in delivering or facilitating better healthcare to provide access to and enable more streamlined delivery of diagnostic testing and care. Its omnichannel platform includes the point-of-care io platform, which puts central-lab quality testing solutions in the hands of clinicians everywhere, and the Company's suite of physician-mediated and medical guideline-driven, at-home sample collection offerings, which bring high-quality testing, population health tools, and seamless digital integration capability to those unable or unwilling to visit a clinic location. binx's FDA-cleared, CLIA-waived io platform is the first ever point-of-care tool for the detection of chlamydia and gonorrhea that provides central lab performance results in about thirty minutes. Its platform is highly flexible, easy-to-use, and rapid, offering molecular point-of-care answers at central-lab quality performance and for the first time enabling single-visit test and treatment. For more information, visit www.mybinxhealth.com . Contacts

binx health Selected as a Top Digital Health Startup that is Transforming the Future of Healthcare -- Named to the 2021 CB Insights Digital Health 150 List

Business Wire
BOSTON--(BUSINESS WIRE)--Dec 14, 2021--
binx health , a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today that CB Insights ranked binx health among the most promising digital health startups in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005380/en/
(Graphic: Business Wire)
The Digital Health 150 is a list of 150 of the top private companies using digital technology to transform healthcare. binx health is included in the Screening, Monitoring, and Diagnostics category. Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. This year's Digital Health 150 was unveiled live during CB Insights' annual Future of Health event. The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns . Companies this year include startups working on data integration and analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more. "This year's Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging," said Brian Lee, SVP of CB Insights' Intelligence Unit. "We are honored to be included in this impressive list of companies that are all helping to reimagine healthcare for coming generations,” said Jeff Luber , binx health chief executive officer. “This recognition is a testament to the innovative spirit, hard work, and sacrifices of our people. It is also further validation that our platform and vision are aligned with the future." About binx health
binx health is a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop. The Company works with large corporate partners and institutions who have access to large patient populations and have a significant interest in delivering or facilitating better healthcare to provide access to and enable more streamlined delivery of diagnostic testing and care. Its omnichannel platform includes the point-of-care io platform, which puts central-lab quality testing solutions in the hands of clinicians everywhere, and the Company's suite of physician-mediated and medical guideline-driven, at-home sample collection offerings, which bring high-quality testing, population health tools, and seamless digital integration capability to those unable or unwilling to visit a clinic location.

Premium
Save for later
NEW YORK ─ University of California San Diego researchers are developing a test to enable rapid, CRISPR-based diagnostic testing at home for infectious diseases such as SARS-CoV-2, with the goal of putting more molecular tests into people's hands. The group is aiming to develop a molecular test with a one-hour turnaround that exceeds the performance of current at-home antigen tests and that could be ready for a submission for regulatory authorization for SARS-CoV-testing in about two years, said Daniel Brogan, a researcher at UCSD who is one of the CRISPR test developers. UCSD said it has inked a joint development agreement with an undisclosed diagnostic test developer with the aim of commercializing its approach, and Brogan and his colleagues recently described the development of their proof-of-concept platform in ACS Sensors, saying they obtained attomolar-level sensitivity using both fluorescence and lateral flow readouts. According to Brogan, the technology may be best suited for low-resource countries without modern healthcare infrastructures, for which the test is being developled for easy deployment. However, he and his colleagues ultimately plan to develop inexpensive assays that could be used for testing anywhere and for many indications, including in the home. The CRISPR-based platform they are developing achieves its one-hour time to result through the use of isothermal amplification, which is a fast way to amplify SARS-CoV-2 because it uses only one thermal cycle. Isothermal amplification is needed so the test can reach a level of sensitivity required for SARS-CoV-2 and other infectious disease tests, but it often leads to a low level of specificity and that in turn can produce high rates of false positives, Brogan noted. MIT researcher Helena de Puig, who is not affiliated with the UCSD work said that when Cas enzymes are combined with isothermal amplification, they add both sensitivity and specificity in infectious disease diagnostic testing. She is the first author of a paper published recently in Science Advances describing the development of a CRISPR-based, low-cost, point-of-care diagnostic that the researchers said can detect SARS-CoV-2 from unprocessed patient saliva in about one hour. "CRISPR-Cas enzymes have evolved to recognize specific nucleic acid sequences, so they are highly specific to their targets," she said, adding, "They also increase the sensitivity of isothermal amplification due to their additional catalytic activity while cleaving the reporter nucleic acids." Cas13d has a preference for a sequence designed into the modified reporter probe, and each reporter can be designed to detect a specific genomic sequence. "The means the system is reprogrammable, so you just change what you want to target, and detect a single change in a sequence," Brogan said, adding that it may be possible to develop many variations of the reporter probe, enabling multiplexing and the detection of multiple sequences in one reaction. According to Cesar Castro, a point-care-diagnostic test developer and director of the cancer program at Boston-based Mass General Hospital Cancer Center, Cas13d "is not super unique but certainly has competitive advantages" over other CRISPR enzyme subtype subtypes including efficiency. Still, there are important near and intermediate term obstacles that could hinder the deployment of such tests, including access to reagents "that, due to proprietary and commercial factors, still create bottlenecks," said Castro, who is not affiliated with UCSD but is leading the development of CRISPR-based detection of the human papillomavirus for cervical cancer screening. Regardless, several firms are developing, or have developed, CRISPR-based diagnostic tests to detect SARS-CoV-2. For example, Sherlock Biosciences has developed and commercialized its SHERLOCK platform, named for Specific High-sensitivity Enzymatic Reporter unlocking, which combines enzymes such as Cas13, Cas12a, and Csm6 to allow for the simultaneous detection of multiple nucleic acids. The firm announced in May 2020 that it had received Emergency Use Authorization from the US Food and Drug Administration for its Sherlock CRISPR SARS-CoV-2 kit designed for use in high-volume CLIA laboratories and hospitals. Additionally, Sherlock and Mammoth Biosciences have signed partnership deals with other firms — Sherlock Bio with Binx Health and Mammoth with the consumer healthcare arm of pharmaceutical company GlaxoSmithKline — to develop and commercialize rapid CRISPR-based point-of-care or home-use diagnostic tests for COVID-19. Because UCSD's technology could potentially address other medical indications,  the group is exploring its use to detect the dengue virus, Brogan said. However, the group doesn't want to be limited "just one or two diseases," he said, adding, "We think this technology is more of a platform that is generalizable for many conditions." The group has some challenging work ahead of it to move the platform closer to commercialization. The system has been developed to use nasopharyngeal samples for testing, but the group is interested in developing it to test saliva samples, Brogan said. It also needs to automate the extraction of RNA from samples, and for that it will seek a collaboration with groups that have developed advanced extraction methods, he added. The UCSD researchers aim to provide a SARS-CoV-2 test that costs less than $5, which should make it easily adoptable for home use, Brogan said. "Though we are not there yet, we've taken a big step toward putting CRISPR diagnostic tests into people's hands," Brogan said.

UCSD Developing SARS-CoV-2 At-Home, Molecular Test Leveraging CRISPR, Isothermal Amplification

With STIs on the rise, Wellfleet takes leadership role in offering its college partners convenient, accurate, and discreet at-home solutions for sexual health
Download
December 08, 2021 08:00 AM Eastern Standard Time
BOSTON--( BUSINESS WIRE )--binx health, through an expanded agreement with student health insurer Wellfleet, will provide college students nationwide access to sexually transmitted infection (STI) testing. The agreement will enable students from all colleges and universities offering student health insurance from Wellfleet, a Berkshire Hathaway company and one of the nation’s largest student health insurance carriers, access to testing through the binx everywhere at-home and in-dorm digital platform from binx health, a healthcare technology and diagnostics company that brings convenient care to the locations where people live, work, study, and shop. Enhancing access to STI testing is vital for the college population as college and university students are among the highest-risk populations for acquiring STIs. According to the Centers for Disease Control and Prevention, nearly 50% of the 26 million new STIs diagnosed in 2018 were among young people between the ages of 15–24 years.1
“The healthcare needs of the student population are unique and evolving,” said Drew DiGiorgio, President and CEO of Wellfleet. “We’re hyper-focused on delivering a positive experience for our members through clinical programs designed to improve access to care. Our agreement with binx in COVID-19 testing, and now in STI testing, is emblematic of this mission and we look forward to working together to continue to reach populations with high quality care in the places most convenient for them.”
Despite the availability of highly accurate tests, the uptake of routine STI screening for young people is low—estimated in one study to be under 12%2—and has been attributed to numerous factors including the stigma associated with attending STI clinics, embarrassment, and the inconvenience of attending a brick-and-mortar testing location.3
“Delivering on the promise of better healthcare means linking arms with those of similar commitment who are driven to address old problems in new ways,” said Jeffrey Luber, binx CEO. “We applaud Wellfleet’s commitment to its members by putting students, high quality care, and convenience at the center of a new care paradigm in sexual health.”
While infection rates continue to rise, in-person patient care remains severely impacted due to the COVID pandemic4. The emergence of at-home and in-dorm access like binx everywhere, offers the potential to address many key barriers, while still providing quality, comprehensive care. In 2020, binx and Wellfleet announced an agreement to offer college clients access to convenient at-home and in-dorm sample collection for COVID-19 testing using binx’s enterprise solutions for population health screening. About binx health
Binx health is a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop. The Company works with large corporate partners and institutions who have access to large patient populations and have a significant interest in delivering or facilitating better healthcare to provide access to and enable more streamlined delivery of diagnostic testing and care. Its omnichannel platform includes the point-of-care io platform which puts central-lab quality testing solutions in the hands of clinicians everywhere and the Company's suite of physician-mediated and medically guideline-driven, at-home sample collection offerings which bring high quality testing, population health tools and seamless digital integration capability to those unable or unwilling to visit a clinic location. binx's FDA-cleared, CLIA-waived io platform is the first ever point-of-care tool for the detection of chlamydia and gonorrhea that provides central lab performance results in about thirty minutes. Its platform is highly flexible, easy-to-use, and rapid, offering molecular point-of-care answers at central-lab quality performance and for the first time enabling single-visit test and treatment. For more information, visit www.mybinxhealth.com . About Wellfleet
Wellfleet is a Berkshire Hathaway company focused on delivering customer-centric insurance solutions through flexible product offerings and quality service. With an A++ (Superior) financial strength rating from A.M. Best*, Wellfleet’s goal is to protect people against risk throughout every stage of life — from grade school to college, the workplace, and beyond. Headquartered in Springfield, Mass., Wellfleet was founded in 1993 and is one of the leading providers of health and accident insurance products to the higher education market. Additionally, Wellfleet’s Workplace division delivers high-quality, customizable benefit solutions through a suite of voluntary products, including Accident, Critical Illness and Short-Term Disability Income insurance. For more information, visit www.wellfleetinsurance.com
Wellfleet is the marketing name used to refer to the insurance and administrative operations of Wellfleet Insurance Company, Wellfleet New York Insurance Company, and Wellfleet Group, LLC. All insurance products are administered or managed by Wellfleet Group, LLC. Product availability is based upon business and/or regulatory approval and may differ among companies. *For latest rating, visit ambest.com. ______________________
1 Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, Centers for Disease Control and Prevention, Published January 2021. https://www.cdc.gov/std/life-stages-populations/adolescents-youngadults.htm
2 Sexually Transmitted Infection Testing Among Adolescents and Young Adults in the United States (2016). https://www.jahonline.org/action/showPdf?pii=S1054-139X%2816%2900019-7

binx health and Student Health Insurer, Wellfleet, Expand Agreement in College Health for In-Dorm and At-Home Access to Testing for Sexually Transmitted Infections (STIs)

McKesson

Binx Health Inks US Distribution Agreement With McKesson for Chlamydia, Gonorrhea Testing Platform

Sherlock Biosciences

Polar Speed

Binx Health

Good Start Genetics

SynapDx

Exact Sciences

Kaon Interactive

University of Oxford

OmniSeq

Myriad Genetics

Eli Lilly and Company

Shell Oil Company

Molecular Sensing

University of Bath

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Startups focused on providing products and services catering to women's health and wellbeing.

Women's Health & Wellness

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Medical Devices

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Health Monitoring & Diagnostics

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Omics

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Digital Health

The winners of the third annual CB Insights Digital Health 150.

Digital Health 150

Series B

Series B - II

Series C

Series D

Series E

Series D - II

Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.

Name	Firm	Work History	Other Seats
John Clarkson			Binx Health
Neil Butler		Neil is an IVD specialist with over 20 years’ experience managing global medical diagnostic companies. Neil serves on the Board of Nidor Dx, Radisens and Spectromics and was previously Chair and Non-Executive Director for Atlas Genetics / Binx Health and Genomic Vision.	Binx Health

Name	John Clarkson	Neil Butler
Firm
Work History		Neil is an IVD specialist with over 20 years’ experience managing global medical diagnostic companies. Neil serves on the Board of Nidor Dx, Radisens and Spectromics and was previously Chair and Non-Executive Director for Atlas Genetics / Binx Health and Genomic Vision.
Other Seats	Binx Health	Binx Health

Name	Work History	Title	Status
Jeffrey Luber	Good Start Genetics, SynapDx, Exact Sciences, and Kaon Interactive	Chief Executive Officer	Current
Anna Dixon	University of Oxford	Chief Technology Officer	Current
Mark Aguillard	OmniSeq, Myriad Genetics, Eli Lilly and Company, and Shell Oil Company	Chief Commercial Officer	Current
John Clarkson	Molecular Sensing, and University of Bath	Chief Executive Officer	Former

Name	Jeffrey Luber	Anna Dixon	Mark Aguillard	John Clarkson
Work History	Good Start Genetics, SynapDx, Exact Sciences, and Kaon Interactive	University of Oxford	OmniSeq, Myriad Genetics, Eli Lilly and Company, and Shell Oil Company	Molecular Sensing, and University of Bath
Title	Chief Executive Officer	Chief Technology Officer	Chief Commercial Officer	Chief Executive Officer
Status	Current	Current	Current	Former

Predict your next investment

Binx Health

See what CB Insights has to offer

Executives

Board of Directors

Binx Health Board of Directors

Binx Health Management Team

4 Team Members

CB Insights uses Cookies